Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three pharmaceutical agents: - **Amoxicillin** is a broad-spectrum, beta-lactam antibiotic in the penicillin class that inhibits bacterial cell wall synthesis, leading to bacterial cell death. - **Clavulanic acid** is a beta-lactamase inhibitor that protects amoxicillin from degradation by beta-lactamase enzymes produced by resistant bacteria, thereby extending the antibacterial spectrum of amoxicillin[6][7]. - **Fluconazole** is an antifungal agent belonging to the triazole class. It works by inhibiting fungal cytochrome P450 enzyme 14α-demethylase, which disrupts ergosterol synthesis and impairs fungal cell membrane formation[2]. This combination would theoretically provide coverage against both susceptible bacterial and fungal pathogens. However, there are no widely recognized fixed-dose products or brand names for this exact triple combination; it may be used off-label in clinical scenarios where mixed infections (bacterial and fungal) are present or suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clavulanic acid + fluconazole.